{
  "title": "Paper_165",
  "abstract": "pmc ACS Omega ACS Omega 3686 acsomega ao ACS Omega 2470-1343 American Chemical Society http://pubs.acs.org/journal/acsodf PMC12489669 PMC12489669.1 12489669 12489669 10.1021/acsomega.5c07360 1 Article Exploring Regioisomeric\nIndole–Furanone Tubulin\nInhibitors 7765258 Venettozzi Marcella 7765209 Coburn Taylor E. 6475951 Evans Blake A. 7765214 Grillo Merrelle S. 7765292 Le Aivy N. 7765297 Minayev Alex M. 7765242 Muse Ameer H. 7765221 Otchere Joed G. 7765207 Potvin Keira L. 7765250 Staunton Aidan P. 7765253 Watroba Charles M. 7769006 Williams Delaney M. 5616926 Cole Kathryn E. 3930442 Mowery Patricia 248439 https://orcid.org/0000-0001-8882-9128 Pelkey Erin T.  † Department\nof Chemistry 3494 Hobart and William Smith Colleges Geneva New York 14456 United States  ‡ Department\nof Biology Hobart and William Smith Colleges Geneva New York 14456 United States  § Department\nof Molecular Biology and Chemistry 6013 Christopher\nNewport University Newport\nNews Virginia 23606 United States * pelkey@hws.edu * mowery@hws.edu * kathryn.cole@cnu.edu 21 9 2025 30 9 2025 10 38 498176 44675 44682 28 7 2025 16 9 2025 11 9 2025 21 9 2025 21 09 2025 03 10 2025 03 10 2025 © 2025 The Authors. Published by American Chemical Society 2025 The Authors https://creativecommons.org/licenses/by/4.0/ This article is licensed under CC-BY 4.0 Tubulin is involved in microtubule function and affects\nmitosis,\ncell shape, migration, and the movement of organelles. Consequently,\ntubulin inhibitors have emerged as promising targets for cancer treatment.\nWe previously identified a novel antitubulin motif that combines a\nfuranone, indole, and electron-rich dimethoxyphenyl ring. The lead\nindole–furanone compound ( 3 3 N N cis National Cancer Institute 10.13039/100000054 R15 CA274493-01A1 Hobart and William Smith Colleges 10.13039/100023584 NA pmc-status-qastatus 0 pmc-status-live yes pmc-status-embargo no pmc-status-released yes pmc-prop-open-access yes pmc-prop-olf no pmc-prop-manuscript no pmc-prop-legally-suppressed no pmc-prop-has-pdf yes pmc-prop-has-supplement yes pmc-prop-pdf-only no pmc-prop-suppress-copyright no pmc-prop-is-real-version no pmc-prop-is-scanned-article no pmc-prop-preprint no pmc-prop-in-epmc yes document-id-old-9 ao5c07360 document-id-new-14 ao5c07360 production-flag-MathML-config-version 3 production-flag-journal-citation-display-style acs-titles production-flag-journal-date-display-style dates-used-rcd-rvd-acc production-flag-si-avail yes document-id-alt-64 356b899aec27e3564effd8c0a1e58ec0c9a2ba0609aa8b7421aeae26174a3703 Published\nas part of ACS Omega special issue Introduction Microtubules are composed of tubulin α/β\ndimers that\npolymerize into protofilament chains. They are dynamic, polymerizing\nand depolymerizing in events called rescue and catastrophe, respectively,\nand are essential for mitosis, cell shape, migration, and the movement\nof organelles.   One important CBS microtubule-targeting\nagent (MTA) is the stilbenoid\nnatural product combretastatin A-4 (CA-4, 1 Combretum caffrum 1 1 2 Figure 1 cis 1 trans 1 cis 1 (a) Colchicine-binding\nsite (CBS) inhibitors; (b) previously studied\ncompounds. We previously explored the use of pyrrolinone  3 3 3 in vitro 3 1 3 Figure To further expand upon the binding and potency of 3 Figure 2 cis cis  2 Rationally designed analogs of 3 Results and Discussion Synthesis We began the synthesis of the focused library\nof 3 3 5 Figure 10 12 Scheme 6 8 6 9 10 7 8 9 11 12 12 9  12 12 12 1 Synthesis of Type-1 Furanones 10 12 We next turned our attention to the synthesis\nof regioisomeric\nType-2 furanones of 20 21 N 18 19 3 N 16 13 14 Scheme 15 N 17 2 Attempted Synthesis of Type-2 Furanones 20 21 We investigated the synthesis of Type-2 furanones 20 21 24 22 Scheme 22 N 23 p 24 24 25 25 24 3 21 29 t 3 Synthesis of Indolylmaleic Anhydrides 29 32 We chose to include the maleic anhydride derivatives\nin our library\nas the cytotoxicity and antitubulin activity of cyclic anhydrides\nremains mostly understudied, with only a few reports to date.  1 Returning\nto the synthesis, this type of transformation leading\nto anhydrides from α-acyloxyketones has been separately communicated\nby Pattabiraman and coworkers utilizing similar conditions to what\nhad been used in the original rofecoxib synthesis (S N 3 24 25 26 27 28 Scheme 29 30 N 31 32 To complete our series\nof analogs, we prepared maleic anhydrides 33 34 5 11 5 11 33 34 Scheme 2 4 Synthesis of Indolylmaleic\nAnhydrides 33 34 Finally, we continued investigating basic conditions\nthat could\nbe used to convert ketoesters 27 28 Scheme  27 21 20 20 21 28 35 36 5 Synthesis of Type-2\nFuranones 20 21 35 36 Cytotoxicity Studies The potencies of the compounds\nwere tested using an MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium\nbromide] assay ( Table 50 50 3 4 5 18 19  1 2 50  1 Cytotoxicity of Compounds in HL-60\nCells  Compound  Heterocycle  X  Y R R  EC  50  +  3 Type-1 Furanone H 2 O H CO 2 1.0 μM ± 0.2 , ,  21 Type-2 Furanone O H 2 H CO 2 >10 μM  29 Anhydride O O H CO 2 Insoluble  5 Type-1 Furanone H 2 O H Me 2.8 μM ± 0.6 ,  18 Type-2 Furanone O H 2 H Me >10 μM  33 Anhydride O O H Me >10 μM  4 Type-1 Furanone H 2 O H H >10 μM  20 Type-2 Furanone O H 2 H H 2.4 μM ± 0.4 , ,  31 Anhydride O O H H >10 μM  12 Type-1 Furanone H 2 O OMe CO 2 >10 μM  35 Type-2 Furanone O H 2 OMe CO 2 0.8 μM ± 0.2 ,  30 Anhydride O O OMe CO 2 insoluble  11 Type-1 Furanone H 2 O OMe Me >10 μM  19 Type-2 Furanone O H 2 OMe Me 1.1 μM ± 0.3 , ,  34 Anhydride O O OMe Me >10 μM  10 Type-1 Furanone H 2 O OMe H >10 μM  36 Type-2 Furanone O H 2 OMe H 0.6 μM ± 0.3 ,  32 Anhydride O O OMe H >10 μM  CA-4 1  - - - - 1.4 nM ± 0.6  Colchicine 2  - - - - 3.0 nM ± 1.0 a Cells were treated with an analog\nconcentration range with eight replicate wells/concentration for 48\nh at 37 °C before addition of MTT and solubilization. Averages\nand standard error from a minimum of three independent experiments\nwere calculated. b EC 50 c Insoluble when increased to 20\nmM in DMSO. d Compounds\nwith the same superscript\nletters (a–c) are statistically overlapping as measured by\nANOVA, where differences are p While 36 50 3 19 35 36 Table 19 35 36 N 1 3 2 N 3 3 The literature regarding\nthe stability of anhydrides in a cellular\nenvironment is less clear; it is possible that they may be modified in vivo Given the encouraging biological results, we examined the general\n“druggability” of the four statistically overlapping\nmost potent compounds. Table S1 Molecular Modeling Studies To further understand inhibitor\nbinding, we turned to molecular modeling. The methoxy A-ring of 36 Figure 36 Table S2 36 19 35 Figure S1 Figure Table S2 3 Molecular modeling of 36 36 36 36 4 Cartoon representation of the main inhibitor-tubulin interactions\nof the most potent trimethoxy inhibitors ( 19 35 36 The dimethoxy analogs, on the other hand, are less\nconsistent in\ntheir binding. Compounds 5 20 Figure S1 5 20 5 20 3 Figure S1 Table S2 While both 3 19 in vitro  3 3 3 Conclusions We set out to systematically examine the\nbiological activity of\na set of 18 indole–furanone analogs based on lead compound 3 N 3 2 N Supplementary Material Financial support of this research was provided\nby the NIH (R15: CA274493), Hobart and William Smith Colleges, and\nChristopher Newport University. Drs. Carey and Cohen, Dr. Ed Franks,\nPatchett Family, and Ed Tapper are gratefully acknowledged for their\nsupport of research at Hobart and William Smith Colleges. Charlie\nFry of SUNY-ESF is acknowledged for his help in acquiring some NMR\nspectra. The Supporting Information is\navailable free of charge at https://pubs.acs.org/doi/10.1021/acsomega.5c07360 Experimental procedures, spectral data, biological data,\nmolecular modeling figures, and copies of 1 13 PDF The manuscript\nwas written collaboratively by K.E.C., P.M., and E.P. based on the\nsynthetic work of E.P., A.H.M., B.A.E., T.E.C., K.L.P., and M.S.G.;\nbiological assays were performed by P.M., M.V., A.P.S., C.M.W., and\nD.M.W.; and modeling studies were performed by K.E.C., A.M.M., A.N.L.,\nand J.G.O. The authors\ndeclare no competing financial interest. Goodson H. V. Jonasson E. M. Microtubules and Microtubule-Associated Proteins Cold Spring Harbor Perspect. Biol 2018 10 a022608 10.1101/cshperspect.a022608 PMC5983186 29858272 Kanakkanthara A. Miller J. H. βIII-tubulin overexpression\nin cancer: Causes,\nconsequences, and potential therapies Biochim.\nBiophys. Acta, Rev. Cancer 2021 1876 188607 10.1016/j.bbcan.2021.188607 34364992 Shuai W. Wang G. Zhang Y. Bu F. Zhang S. Miller D. D. Li W. Ouyang L. Wang Y. Recent Progress\non Tubulin Inhibitors with Dual Targeting Capabilities for Cancer\nTherapy J. Med. Chem 2021 64 7963 7990 10.1021/acs.jmedchem.1c00100 34101463 Podolak M. Holota S. Deyak Y. Dziduch K. Dudchak R. Wujec M. Bielawski K. Lesyk R. Bielawska A. Tubulin inhibitors.\nSelected scaffolds and main trends in the design of novel anticancer\nand antiparasitic agents Bioorg. Chem 2024 143 107076 10.1016/j.bioorg.2023.107076 38163424 Lu Y. Chen J. Xiao M. Li W. Miller D. D. An Overview\nof Tubulin Inhibitors That Interact with the Colchicine Binding Site Pharm. Res 2012 29 2943 2971 10.1007/s11095-012-0828-z 22814904 PMC3667160 Hawash M. Recent Advances\nof Tubulin Inhibitors Targeting the Colchicine Binding Site for Cancer\nTherapy Biomolecules 2022 12 1843 10.3390/biom12121843 36551271 PMC9776383 Pettit G. R. Singh S. B. Hamel E. Lin C. M. Alberts D. S. Garcia-Kendall D. Isolation and structure of the strong cell growth and\ntubulin inhibitor combretastatin A-4 Experientia 1989 45 209 211 10.1007/bf01954881 2920809 Fitzgerald T. J. Molecular\nfeatures of colchicine associated with antimitotic activity and inhibition\nof tubulin polymerization Biochem. Pharmacol 1976 25 1383 1387 10.1016/0006-2952(76)90108-8 938560 Li L. Jiang S. Li X. Liu Y. Su J. Chen J. Recent advances in trimethoxyphenyl\n(TMP) based tubulin inhibitors\ntargeting the colchicine binding site Eur.\nJ. Med. Chem 2018 151 482 494 10.1016/j.ejmech.2018.04.011 29649743 Nam N.-H. Combretastatin\nA-4 analogues as antimitotic antitumor agents Curr. Med. Chem 2003 10 1697 1722 10.2174/0929867033457151 12871118 Arthuis M. Pontikis R. Chabot G. G. Seguin J. Quentin L. Bourg S. Morin-Allory L. Florent J.-C. Synthesis and Structure-Activity\nRelationships of Constrained Heterocyclic Analogues of Combretastatin\nA4 ChemMedchem 2011 6 1693 1705 10.1002/cmdc.201100154 21732536 Mowery P. Banales Mejia F. Franceschi C. L. Kean M. H. Kwansare D. O. Lafferty M. M. Neerukonda N. D. Rolph C. E. Truax N. J. Pelkey E. T. Synthesis\nand evaluation of the anti-proliferative\nactivity of diaryl-3-pyrrolin-2-ones and fused analogs Bioorg. Med. Chem. Lett 2017 27 191 195 10.1016/j.bmcl.2016.11.076 27916489 Hurysz B. Evans B. A. Laryea R. N. Boyer B. E. Coburn T. E. Dexter M. S. Edwards M. A. Faulkner G. V. Huss R. L. Lafferty M. M. Manning M. McNulty M. Melvin S. J. Mitrow C. M. Patel R. R. Pierce K. Russo J. Seminer A. M. Sockett K. A. Webster N. R. Cole K. E. Mowery P. Pelkey E. T. Synthesis, modeling,\nand biological\nevaluation of anti-tubulin indole-substituted furanones Bioorg. Med. Chem. Lett 2023 90 129347 10.1016/j.bmcl.2023.129347 37236376 Mowery P. Filkorn M. M. Hurysz B. Kwansare D. O. Lafferty M. M. McFadden M. A. Neerukonda N. D. Patel R. R. Pierce K. Sockett K. A. Truax N. J. Webster N. R. Pelkey E. T. Discovery\nof an indole-substituted furanone with tubulin polymerization inhibition\nactivity Bioorg. Med. Chem. Lett 2021 41 127991 10.1016/j.bmcl.2021.127991 33775833 Shoemaker R. H. The NCI60\nhuman tumour cell line anticancer drug screen Nat. Rev. Cancer 2006 6 813 823 10.1038/nrc1951 16990858 Yoo K. S. Yoon C. H. Mishra R. K. Jung Y. C. Oxidative\nPalladium­(II) Catalysis: A Highly Efficient and Chemoselective Cross-Coupling\nMethod for Carbon–Carbon Bond Formation under Base-Free and\nNitrogenous-Ligand Conditions J. Am. Chem.\nSoc 2006 128 16384 16393 10.1021/ja063710z 17165795 PMC2602842 Silva N. Abreu A. Ferreira P. M. T. Monteiro L. Queiroz M.-J. R. P. Synthesis\nUsing Suzuki Cross Couplings of Sulfur Analogues of Dehydrotryptophan\nwith a Definite Stereochemistry Eur. J. Org.\nChem 2002 2002 2524 2528 10.1002/1099-0690(200208)2002:15&#x0003c;2524::AID-EJOC2524&#x0003e;3.0.CO;2-W Jung Y. C. Mishra R. K. Yoon C. H. Jung K. W. Oxygen-promoted\nPd­(II) catalysis for the coupling of organoboron compounds and olefins Org. Lett 2003 5 2231 2234 10.1021/ol034458s 12816416 Heller S. T. Schultz E. E. Sarpong R. Chemoselective N-acylation of indoles\nand oxazolidinones with carbonylazoles Angew.\nChem., Int. Ed 2012 51 8304 8308 10.1002/anie.201203976 22786619 Thérien M. Gauthier J. Y. Leblanc Y. Léger S. Perrier H. Prasit P. Wang Z. Synthesis of Rofecoxib,\n(MK 0966, source Vioxx® source 4-(4′-Methylsulfonylphenyl)-3-Phenyl-2­(5H)-Furanone),\na Selective and Orally Active Inhibitor of Cyclooxygenase-2 Synthesis 2001 2001 1778 1779 10.1055/s-2001-17519 Angeles-Dunham V. V. Nickerson D. M. Ray D. M. Mattson A. E. Nitrimines as reagents\nfor metal-free formal C­(sp(2))-C­(sp(2)) cross-coupling reactions Angew. Chem., Int. Ed 2014 53 14538 14541 10.1002/anie.201408613 25365926 Katoh M. Dodo K. Fujita M. Sodeoka M. Structure-activity\nrelationship of N-methyl-bisindolylmaleimide derivatives as cell death\ninhibitors Bioorg. Med. Chem. Lett 2005 15 3109 3113 10.1016/j.bmcl.2005.04.015 15896957 Routier S. Mérour J. Y. Dias N. Lansiaux A. Bailly C. Lozach O. Meijer L. Synthesis and biological evaluation\nof novel phenylcarbazoles as potential anticancer agents J. Med. Chem 2006 49 789 799 10.1021/jm050945x 16420063 Guan Q. Zuo D. Jiang N. Qi H. Zhai Y. Bai Z. Feng D. Yang L. Jiang M. Bao K. Li C. Wu Y. Zhang W. Microwave-assisted synthesis and\nbiological evaluation of 3,4-diaryl maleic anhydride/N-substituted\nmaleimide derivatives as combretastatin A-4 analogues Bioorg. Med. Chem. Lett 2015 25 631 634 10.1016/j.bmcl.2014.12.004 25529737 Pattabiraman V. R. Padakanti S. Veeramaneni V. R. Pal M. Yeleswarapu K. R. Synthesis\nof 3,4-Diarylsubstituted Maleic Anhydride/Maleimide via Unusual Oxidative\nCyclization of Phenacyl Ester/Amide Synlett 2002 2002 947 951 10.1055/s-2002-31901 Uddin M. J. Rao P. N. P. Knaus E. E. Design and synthesis\nof novel rofecoxib\nanalogs as potential cyclooxygenase (COX-2) inhibitors: Replacement\nof the methylsulfonyl pharmacophore by a sulfonylazide bioisostere J. Heterocycl. Chem 2003 40 861 868 10.1002/jhet.5570400518 14604691 Zhou H. B. Comninos J. S. Stossi F. Katzenellenbogen B. S. Katzenellenbogen J. A. Synthesis and evaluation of estrogen receptor ligands\nwith bridged oxabicyclic cores containing a diarylethylene motif:\nestrogen antagonists of unusual structure J.\nMed. Chem 2005 48 7261 7274 10.1021/jm0506773 16279785 Horký P. Voráčová M. Konečná K. Sedlák D. Bartůněk P. Vacek J. Kuneš J. Pour M. Nontoxic combretafuranone analogues\nwith high in vitro antibacterial activity Eur.\nJ. Med. Chem 2018 143 843 853 10.1016/j.ejmech.2017.11.078 29223099 Ning W. Hu Z. Tang C. Yang L. Zhang S. Dong C. Huang J. Zhou H. B. Novel Hybrid Conjugates with Dual\nSuppression of Estrogenic and Inflammatory Activities Display Significantly\nImproved Potency against Breast Cancer J. Med.\nChem 2018 61 8155 8173 10.1021/acs.jmedchem.8b00224 30053783 Mosmann T. Rapid colorimetric\nassay for cellular growth and survival: application to proliferation\nand cytotoxicity assays J. Immunol. Methods 1983 65 55 63 10.1016/0022-1759(83)90303-4 6606682 Gallagher R. Collins S. Trujillo J. McCredie K. Ahearn M. Tsai S. Metzgar R. Aulakh G. Ting R. Ruscetti F. Characterization\nof the continuous, differentiating\nmyeloid cell line (HL-60) from a patient with acute promyelocytic\nleukemia Blood 1979 54 713 733 10.1182/blood.V54.3.713.713 288488 Do\nAmaral D. N. Cavalcanti B. C. Bezerra D. P. Ferreira P. M. P. Castro R. D. P. Sabino J. R. Machado C. M. L. Chammas R. Pessoa C. Sant’anna C. M.\nR. Barreiro E. J. Lima L. M. Docking, synthesis and antiproliferative activity of\nN-acylhydrazone derivatives designed as combretastatin A4 analogues PLoS One 2014 9 e85380 10.1371/journal.pone.0085380 24614859 PMC3948622 Huczyński A. Majcher U. Maj E. Wietrzyk J. Janczak J. Moshari M. Tuszynski J. A. Bartl F. Synthesis, antiproliferative\nactivity and molecular docking of Colchicine derivatives Bioorg. Chem 2016 64 103 112 10.1016/j.bioorg.2016.01.002 26794327 Bukhari S. N. A. Kumar G. B. Revankar H. M. Qin H.-L. Development\nof combretastatins\nas potent tubulin polymerization inhibitors Bioorg. Chem 2017 72 130 147 10.1016/j.bioorg.2017.04.007 28460355 Daina A. Michielin O. Zoete V. SwissADME: a free web tool to evaluate\npharmacokinetics, drug-likeness and medicinal chemistry friendliness\nof small molecules Sci. Rep 2017 7 42717 10.1038/srep42717 28256516 PMC5335600 ",
  "metadata": {
    "Title of this paper": "SwissADME: a free web tool to evaluate\npharmacokinetics, drug-likeness and medicinal chemistry friendliness\nof small molecules",
    "Journal it was published in:": "ACS Omega",
    "URL": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12489669/"
  }
}